Ramipril

Drug Profile

Ramipril

Alternative Names: Acuvil; Altace; Carasel; Delix; HOE 498; Hypren; Pramace; Quark; Ramace; Triatec; Tritace; Unipril; Vesdil

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer AstraZeneca; King Pharmaceuticals; Monarch Pharmaceuticals; Pfizer; Sanofi
  • Class Antihypertensives; Heart failure therapies; Heterocyclic bicyclo compounds; Small molecules
  • Mechanism of Action ACE inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders; Diabetic nephropathies; Heart failure; Hypertension
  • No development reported Ischaemic heart disorders
  • Discontinued Kidney disorders; Type 2 diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Ischaemic-heart-disorders in Turkey (PO, Capsule)
  • 29 Apr 2016 Biomarkers information updated
  • 27 Jul 2015 Sanofi in collaboration with Centre Hospitalier Universitaire de Saint Etienne terminates the PREFACE trial in Atrial fibrillation in France due to difficulty to include patients (NCT00736294)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top